Ribociclib is a prescription anticancer medicine classified as a CDK4/6 inhibitor.

It is used in specific approved treatment settings for certain hormone receptor-positive, HER2-negative breast cancers.

Ribociclib is generally classified as a targeted anticancer therapy rather than traditional chemotherapy.

It inhibits CDK4 and CDK6, proteins involved in regulating cell-cycle progression.

Yes. Ribociclib is an oral medicine.

No. Dose changes must be directed by a qualified healthcare professional.

Blood tests can help monitor blood cell counts and liver function during treatment.

It can reduce certain blood cell counts, which may increase susceptibility to infection.

Contact your healthcare team promptly because fever can be a sign of infection.

Yes. Liver-related abnormalities can occur, which is why monitoring may be required.

Ribociclib can be associated with changes in cardiac electrical activity in some patients.

Do not automatically take an extra dose. Follow your healthcare team's instructions and the official product information.

Do not automatically take another tablet. Contact your healthcare provider or follow official instructions.

Some supplements can interact with prescription medicines. Discuss all supplements with your healthcare team.

Ribociclib may cause harm to an unborn baby. Discuss pregnancy and contraception with your healthcare provider.

Discuss breastfeeding with your healthcare team and follow official prescribing information.

Monitoring can help detect side effects and laboratory abnormalities early.

Do not stop treatment without discussing it with your oncology team.

Follow the storage instructions printed on the official product packaging.

No. This website provides general information and does not replace professional medical advice.